Medindia LOGIN REGISTER
Medindia
Advertisement

David McGirr Joins LifeCell Board of Directors

Monday, November 12, 2007 General News
Advertisement
BRANCHBURG, N.J., Nov. 12 LifeCell Corporation(Nasdaq: LIFC) announced today that David W. J. McGirr joined the Company'sBoard of Directors and also will serve as Chairman of the Audit Committee.
Advertisement

Mr. McGirr is Senior Vice President and CFO at Cubist Pharmaceuticals,Inc. (Nasdaq: CBST) and has served in his current position since November2002. He also served as Treasurer of Cubist from November 2002 until January2003. From 1999 to 2002, Mr. McGirr was the President and Chief OperatingOfficer of hippo, inc., an internet technology, venture-financed company. Mr.McGirr served as a member of hippo's Board of Directors from 1999 to 2003.From 1996 to 1999, he was the President of GAB Robins North America, Inc., arisk management company, serving also as Chief Executive Officer from 1995 to1996. Mr. McGirr was a private equity investor from 1995 to 1996. From 1978to 1995, Mr. McGirr served in various positions within the S.G. Warburg Group,ultimately as Chief Financial Officer, Chief Administrative Officer andManaging Director of S.G. Warburg & Co., Inc., a position he held from 1992 to1995. Mr. McGirr received a B.Sc. in Civil Engineering from the University ofGlasgow and received an M.B.A. from the Wharton School at the University ofPennsylvania.
Advertisement

"I believe that David's diversified experience and successful track recordmake him a valuable addition to our Board," said Paul G. Thomas, President andChief Executive Officer of LifeCell.

The Company also announced that Michael Cahr is leaving the LifeCell Boardafter having been involved with the company for nearly twenty years andserving as a director for more than fifteen years. Michael is leaving theboard to devote full time to his role as a Partner at Focus Equity Partners,an Oak Brook, Illinois based private equity firm. Mr. Cahr joined the Board in1991 and during his tenure served as Chairman of both the Compensation andAudit Committees. "Michael played a major role in LifeCell's early stages ofdevelopment and we want to recognize and thank him for his invaluablecontributions as a board member over the years," Mr. Thomas noted.

About LifeCell

LifeCell develops and markets innovative biologically-based products inthe emerging field of regenerative medicine for use in reconstructive,orthopedic and urogynecologic surgical procedures. LifeCell's currentmarketed products include: AlloDerm(R), for plastic reconstructive, generalsurgical, burn and periodontal procedures; Cymetra(R), a particulate form ofAlloDerm(R) suitable for injection; GraftJacket(R), for orthopedicapplications and lower extremity wounds; AlloCraft(R)DBM, for bone graftingprocedures; and Repliform(R), for urogynecologic surgical procedures. TheCompany's research and development initiatives include programs designed toextend the use of its current marketed regenerative tissue matrix productsinto new surgical applications as well as expanding its product line in therapidly growing biosurgery market. LifeCell maintains a website atwww.lifecell.com.

SOURCE LifeCell Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close